Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins

Nanocarriers have been developed in order to protect drugs or to improve drugs efficiency by reaching the damaged tissue and avoiding systemic and local toxicity. By using HSP90 inhibitors, some cancer drug resistances have been overcome and the loading into nanocarriers of such drugs has shown an i...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathieu, Clélia, Messaoudi, Samir, Fattal, Elias, Vergnaud-Gauduchon, Juliette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992530/
https://www.ncbi.nlm.nih.gov/pubmed/35582577
http://dx.doi.org/10.20517/cdr.2019.26
_version_ 1784683748243013632
author Mathieu, Clélia
Messaoudi, Samir
Fattal, Elias
Vergnaud-Gauduchon, Juliette
author_facet Mathieu, Clélia
Messaoudi, Samir
Fattal, Elias
Vergnaud-Gauduchon, Juliette
author_sort Mathieu, Clélia
collection PubMed
description Nanocarriers have been developed in order to protect drugs or to improve drugs efficiency by reaching the damaged tissue and avoiding systemic and local toxicity. By using HSP90 inhibitors, some cancer drug resistances have been overcome and the loading into nanocarriers of such drugs has shown an increase of their activities. This review will present some advantages of HSP90 inhibitors to treat resistant tumors; especially those targeting the mitochondrial protein TRAP1. We will also focus on the targeting of the primary tumors, cancer stem cells and metastatic cells.
format Online
Article
Text
id pubmed-8992530
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher OAE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-89925302022-05-16 Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins Mathieu, Clélia Messaoudi, Samir Fattal, Elias Vergnaud-Gauduchon, Juliette Cancer Drug Resist Review Nanocarriers have been developed in order to protect drugs or to improve drugs efficiency by reaching the damaged tissue and avoiding systemic and local toxicity. By using HSP90 inhibitors, some cancer drug resistances have been overcome and the loading into nanocarriers of such drugs has shown an increase of their activities. This review will present some advantages of HSP90 inhibitors to treat resistant tumors; especially those targeting the mitochondrial protein TRAP1. We will also focus on the targeting of the primary tumors, cancer stem cells and metastatic cells. OAE Publishing Inc. 2019-09-19 /pmc/articles/PMC8992530/ /pubmed/35582577 http://dx.doi.org/10.20517/cdr.2019.26 Text en © The Author(s) 2019. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2019. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Mathieu, Clélia
Messaoudi, Samir
Fattal, Elias
Vergnaud-Gauduchon, Juliette
Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins
title Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins
title_full Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins
title_fullStr Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins
title_full_unstemmed Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins
title_short Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins
title_sort cancer drug resistance: rationale for drug delivery systems and targeted inhibition of hsp90 family proteins
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992530/
https://www.ncbi.nlm.nih.gov/pubmed/35582577
http://dx.doi.org/10.20517/cdr.2019.26
work_keys_str_mv AT mathieuclelia cancerdrugresistancerationalefordrugdeliverysystemsandtargetedinhibitionofhsp90familyproteins
AT messaoudisamir cancerdrugresistancerationalefordrugdeliverysystemsandtargetedinhibitionofhsp90familyproteins
AT fattalelias cancerdrugresistancerationalefordrugdeliverysystemsandtargetedinhibitionofhsp90familyproteins
AT vergnaudgauduchonjuliette cancerdrugresistancerationalefordrugdeliverysystemsandtargetedinhibitionofhsp90familyproteins

Ejemplares similares